NSCLC

[BioNTech SE] BioNTech SE announced the expansion of its strategic collaboration with Regeneron to advance the company’s FixVac candidate BNT116 in combination with Libtayo®, a PD-1 inhibitor, in advanced non-small cell lung cancer.

[Genprex, Inc.] Genprex, Inc. announced that the first patient was dosed in the Acclaim-1 clinical trial, an open-label, multi-center Phase I/II clinical trial evaluating REQORSA™ Immunogene Therapy, in combination with Tagrisso® (osimertinib) in patients with late-stage NSCLC.

[AnHeart Therapeutics] AnHeart Therapeutics together with Innovent Biologics, Inc. jointly announced that the Center for Drug Evaluation of China’s Nation Medical Products Administration (NMPA) has granted Breakthrough Therapy Designation to taletrectinib.

[Molecular Cancer Research] Pharmacologic inhibition of mTOR kinase by Torin2 significantly sensitized lung squamous cell carcinoma cell lines to ionizing radiation.

[npj Precision Oncology] STAT3 inhibition effectively suppressed the adaptive survival of anaplastic lymphoma kinase (ALK)-rearranged lung cancer cells by enhancing ALK inhibition-induced apoptosis.

[British Journal of Cancer] Researchers reported a novel blood-based biomarker panel for early diagnosis, monitoring of therapeutic response, and prognostic evaluation of patients with NSCLC brain metastasis.